BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

880 related articles for article (PubMed ID: 28190762)

  • 1. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial.
    Erlandsson J; Holm T; Pettersson D; Berglund Å; Cedermark B; Radu C; Johansson H; Machado M; Hjern F; Hallböök O; Syk I; Glimelius B; Martling A
    Lancet Oncol; 2017 Mar; 18(3):336-346. PubMed ID: 28190762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
    Bahadoer RR; Dijkstra EA; van Etten B; Marijnen CAM; Putter H; Kranenbarg EM; Roodvoets AGH; Nagtegaal ID; Beets-Tan RGH; Blomqvist LK; Fokstuen T; Ten Tije AJ; Capdevila J; Hendriks MP; Edhemovic I; Cervantes A; Nilsson PJ; Glimelius B; van de Velde CJH; Hospers GAP;
    Lancet Oncol; 2021 Jan; 22(1):29-42. PubMed ID: 33301740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
    Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L
    Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study.
    Bach SP; Gilbert A; Brock K; Korsgen S; Geh I; Hill J; Gill T; Hainsworth P; Tutton MG; Khan J; Robinson J; Steward M; Cunningham C; Levy B; Beveridge A; Handley K; Kaur M; Marchevsky N; Magill L; Russell A; Quirke P; West NP; Sebag-Montefiore D;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):92-105. PubMed ID: 33308452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.
    Duchesne GM; Woo HH; Bassett JK; Bowe SJ; D'Este C; Frydenberg M; King M; Ledwich L; Loblaw A; Malone S; Millar J; Milne R; Smith RG; Spry N; Stockler M; Syme RA; Tai KH; Turner S
    Lancet Oncol; 2016 Jun; 17(6):727-737. PubMed ID: 27155740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial.
    van Gijn W; Marijnen CA; Nagtegaal ID; Kranenbarg EM; Putter H; Wiggers T; Rutten HJ; Påhlman L; Glimelius B; van de Velde CJ;
    Lancet Oncol; 2011 Jun; 12(6):575-82. PubMed ID: 21596621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT.
    Brunt AM; Haviland JS; Wheatley DA; Sydenham MA; Bloomfield DJ; Chan C; Cleator S; Coles CE; Donovan E; Fleming H; Glynn D; Goodman A; Griffin S; Hopwood P; Kirby AM; Kirwan CC; Nabi Z; Patel J; Sawyer E; Somaiah N; Syndikus I; Venables K; Yarnold JR; Bliss JM;
    Health Technol Assess; 2023 Nov; 27(25):1-176. PubMed ID: 37991196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
    Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA
    Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
    Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
    Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04.
    Ngan SY; Burmeister B; Fisher RJ; Solomon M; Goldstein D; Joseph D; Ackland SP; Schache D; McClure B; McLachlan SA; McKendrick J; Leong T; Hartopeanu C; Zalcberg J; Mackay J
    J Clin Oncol; 2012 Nov; 30(31):3827-33. PubMed ID: 23008301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiotherapy regimens for rectal cancer: long-term outcomes and health-related quality of life in the Stockholm III trial.
    Erlandsson J; Fuentes S; Radu C; Frödin JE; Johansson H; Brandberg Y; Holm T; Glimelius B; Martling A
    BJS Open; 2021 Nov; 5(6):. PubMed ID: 35040942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial.
    Chow E; van der Linden YM; Roos D; Hartsell WF; Hoskin P; Wu JS; Brundage MD; Nabid A; Tissing-Tan CJ; Oei B; Babington S; Demas WF; Wilson CF; Meyer RM; Chen BE; Wong RK
    Lancet Oncol; 2014 Feb; 15(2):164-71. PubMed ID: 24369114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial.
    van der Pas MH; Haglind E; Cuesta MA; Fürst A; Lacy AM; Hop WC; Bonjer HJ;
    Lancet Oncol; 2013 Mar; 14(3):210-8. PubMed ID: 23395398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
    Bosset JF; Calais G; Mineur L; Maingon P; Stojanovic-Rundic S; Bensadoun RJ; Bardet E; Beny A; Ollier JC; Bolla M; Marchal D; Van Laethem JL; Klein V; Giralt J; Clavère P; Glanzmann C; Cellier P; Collette L;
    Lancet Oncol; 2014 Feb; 15(2):184-90. PubMed ID: 24440473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial.
    Coles CE; Griffin CL; Kirby AM; Titley J; Agrawal RK; Alhasso A; Bhattacharya IS; Brunt AM; Ciurlionis L; Chan C; Donovan EM; Emson MA; Harnett AN; Haviland JS; Hopwood P; Jefford ML; Kaggwa R; Sawyer EJ; Syndikus I; Tsang YM; Wheatley DA; Wilcox M; Yarnold JR; Bliss JM;
    Lancet; 2017 Sep; 390(10099):1048-1060. PubMed ID: 28779963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial.
    Sebag-Montefiore D; Stephens RJ; Steele R; Monson J; Grieve R; Khanna S; Quirke P; Couture J; de Metz C; Myint AS; Bessell E; Griffiths G; Thompson LC; Parmar M
    Lancet; 2009 Mar; 373(9666):811-20. PubMed ID: 19269519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial.
    Wang SL; Fang H; Song YW; Wang WH; Hu C; Liu YP; Jin J; Liu XF; Yu ZH; Ren H; Li N; Lu NN; Tang Y; Tang Y; Qi SN; Sun GY; Peng R; Li S; Chen B; Yang Y; Li YX
    Lancet Oncol; 2019 Mar; 20(3):352-360. PubMed ID: 30711522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Robotic versus laparoscopic surgery for middle and low rectal cancer (REAL): short-term outcomes of a multicentre randomised controlled trial.
    Feng Q; Yuan W; Li T; Tang B; Jia B; Zhou Y; Zhang W; Zhao R; Zhang C; Cheng L; Zhang X; Liang F; He G; Wei Y; Xu J;
    Lancet Gastroenterol Hepatol; 2022 Nov; 7(11):991-1004. PubMed ID: 36087608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.